Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The BIR2 (Baculovirus IAP Repeat 2) domain of the X-linked inhibitor of apoptosis protein (XIAP) is a specialized protein module that plays a dual role in regulating cell death and immune signaling. It is the primary site through which XIAP binds and directly inhibits the effector caspases, caspase-3 and caspase-7, thereby halting the apoptotic cascade and promoting cell survival [PubMed, Frontiers in Oncology]. Additionally, the BIR2 domain functions as a critical scaffold for the kinase RIPK2 within the NOD2 signaling pathway, facilitating the innate immune response to bacterial pathogens [PubMed, EMBO Molecular Medicine]. In oncology, the overexpression of XIAP and its BIR2 domain is associated with resistance to chemotherapy and poor prognosis, as it prevents cancer cells from undergoing programmed cell death [Frontiers in Oncology, PubMed]. Therapeutic strategies targeting this domain include Smac mimetics, which occupy the BIR2 binding groove to displace caspases and sensitize tumors to apoptosis-inducing agents [PubMed]. However, because of its essential role in immune homeostasis, mutations in the BIR2 domain are linked to severe inflammatory conditions, such as X-linked lymphoproliferative syndrome type 2 (XLP2) and refractory inflammatory bowel disease [EMBO Molecular Medicine, PubMed].
Antagonism of the IAP-binding motif (IBM) groove to displace effector caspases (Caspase-3/7) and inhibition of the XIAP-RIPK2 interaction to block NOD2-dependent NF-kappaB signaling
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on X-linked inhibitor of apoptosis protein, BIR2 domain (XIAP-BIR2).